The influence of magnetic and physiological behaviour on the effectiveness of iron oxide nanoparticles for hyperthermia

被引:58
作者
Dennis, C. L. [1 ]
Jackson, A. J. [2 ,3 ]
Borchers, J. A. [2 ]
Ivkov, R. [4 ]
Foreman, A. R. [4 ]
Hoopes, P. J. [5 ]
Strawbridge, R. [5 ]
Pierce, Z. [5 ]
Goerntiz, E. [6 ]
Lau, J. W. [1 ]
Gruettner, C. [7 ]
机构
[1] NIST, Mat Sci & Engn Lab, Gaithersburg, MD 20899 USA
[2] NIST, Ctr Neutron Res, Gaithersburg, MD 20899 USA
[3] Univ Maryland, Dept Mat Sci & Engn, College Pk, MD 20742 USA
[4] Triton BioSyst Inc, Chelmsford, MA 01824 USA
[5] Dartmouth Coll, Hanover, NH 03755 USA
[6] Fraunhofer Inst Angew Polymerforsch, D-14476 Potsdam, Germany
[7] Micromod Partikeltechnol GmbH, D-18119 Rostock, Germany
关键词
D O I
10.1088/0022-3727/41/13/134020
中图分类号
O59 [应用物理学];
学科分类号
摘要
Magnetic nanoparticles are being developed for a wide range of biomedical applications. In particular, hyperthermia involves heating the magnetic nanoparticles through exposure to an alternating magnetic field. These materials offer the potential to selectively treat cancer by heating cancer tissue locally and at the cellular level. This may be a successful method if there are enough particles in a tumor possessing a sufficiently high specific absorption rate (SAR) to deposit heat quickly while minimizing thermal damage to surrounding tissue. High SAR magnetic nanoparticles have been developed and used in mouse models of cancer. The magnetic nanoparticles comprise iron oxide magnetic cores (mean core diameter of 50 nm) surrounded by a dextran layer shell for colloidal stability. In comparing two similar systems, the saturation magnetization is found to play a crucial role in determining the SAR, but is not the only factor of importance. (A difference in saturation magnetization of a factor of 1.5 yields a difference in SAR of a factor of 2.5 at 1080 Oe and 150 kHz.) Variations in the interactions due to differences in the dextran layer, as determined through neutron scattering, also play a role in the SAR. Once these nanoparticles are introduced into the tumor, their efficacy, with respect to tumor growth, is determined by the location of the nanoparticles within or near the tumor cells and the association of the nanoparticles with the delivered alternating magnetic field (AMF). This association (nanoparticle SAR and AMF) determines the amount of heat generated. In our setting, the heat generated and the time of heating (thermal dose) provides a tumor gross treatment response which correlates closely with that of conventional (non-nanoparticle) hyperthermia. This being said, it appears specific aspects of the nanoparticle hyperthermia cytopathology mechanism may be very different from that observed in conventional cancer treatment hyperthermia.
引用
收藏
页数:5
相关论文
共 19 条
[11]  
Izzo F, 2001, Adv Surg, V35, P225
[12]   Radiofrequency ablation of breast cancer -: First report of an emerging technology [J].
Jeffrey, SS ;
Birdwell, RL ;
Ikeda, DM ;
Daniel, BL ;
Nowels, KW ;
Dirbas, FM ;
Griffey, SM .
ARCHIVES OF SURGERY, 1999, 134 (10) :1064-1068
[13]   Reduction and analysis of SANS and USANS data using IGOR Pro [J].
Kline, Steven R. .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 2006, 39 :895-900
[14]   Magnetically mediated hyperthermia: current status and future directions [J].
Moroz, P ;
Jones, SK ;
Gray, BN .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2002, 18 (04) :267-284
[15]   Tumor response to arterial embolization hyperthermia and direct injection hyperthermia in a rabbit liver tumor model [J].
Moroz, P ;
Jones, SK ;
Gray, BN .
JOURNAL OF SURGICAL ONCOLOGY, 2002, 80 (03) :149-156
[16]  
Overgaard J., 1985, Hyperthermic Oncol., V2, P8
[17]  
Streffer C, 1987, Recent Results Cancer Res, V104, P24
[18]   Heating the patient: a promising approach? [J].
van der Zee, J .
ANNALS OF ONCOLOGY, 2002, 13 (08) :1173-1184
[19]   Hyperthermia and hypoxia: new developments in anticancer chemotherapy [J].
Zaffaroni, N ;
Fiorentini, G ;
De Giorgi, U .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (04) :340-342